Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer

Cancer Research

Volumn 62, Issue 18, 2002, Pages 5210-5217

  Joensuu, Heikki ^a,b   Anttonen, Anu ^a   Eriksson, Minna ^b   Mäkitaro, Riitta ^c   Alfthan, Henrik ^a   Kinnula, Vuokko ^c   Leppä, Sirpa ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; SYNDECAN 1;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEOGLYCANS; SURVIVAL RATE; SYNDECAN-1; SYNDECANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037105784     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Functions of cell surface heparan sulfate proteoglycans
2. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns
3. The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction
4. Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor
5. Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth
6. Fibroblast growth factor-2
7. Fibroblast growth factor-2
8. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity
9. Syndecan-1 expression inhibits myoblast differentiation through a basic fibroblast growth factor-dependent mechanism
10. Regulation of basic fibroblast growth factor binding and activity by cell density and heparan sulfate
11. The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner
12. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metaloproteinase
13. Drosophila syndecan: Conservation of a cell surface heparan sulfate proteoglycan
14. Serum syndecan-1: A new independent prognostic marker in multiple myeloma
15. Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bfgf binding following elastase-induced injury
16. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation
17. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
18. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients
19. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
20. Syndecan-1 expression has prognostic significance in head and neck carcinoma
21. Syndecan-1: A new prognostic marker in laryngeal cancer
22. Syndecan-1 expression in malignant mesothelioma: Correlation with cell differentiation, WT1 expression, and clinical outcome
23. Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma
24. Three-year results of the Finnish prostate cancer screening trial
25. Identification and location on syndecan-1 core protein epitopes of B-B2 and B-B4 monoclonal antibodies
26. A high pretreatment serum bFGF concentration is an independent predictor of poor prognosis in non-Hodgkin’s lymphoma
27. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery
28. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor
29. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers
30. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma
31. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential
32. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells
33. TGF-β regulates production of growth factors and TGF-β by human peripheral blood monocytes
34. Basic fibroblast growth factor secreted by an animal tumor is detectable in urine
35. Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor
36. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers
37. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis
38. Reduced integrin α3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung
39. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer
40. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer
41. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer
42. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer
43. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN, and MYC in patients with squamous cell lung carcinomas